DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Sector Allocation
- Healthcare89.9%$8.6B
- Other9.5%$906.6M
- Technology0.6%$61.4M
AUM History
13fpro.ai/research/fund/deerfield-management-company-l-p-series-c-1009258
Conviction and streaks
Concentrating · top 10 = 53.2%From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.
Largest positions — Q2 2026
NUVL
$2.1B- BROOKDALE$585.7M
RVMD
$448.0MPRAX
$322.5MVTRS
$320.9MCNC
$314.6M- $251.7M
UTHR
$247.6M- ARROWHEAD$240.5M
LEGN
$235.0MCOGT
$193.7MGMAB
$188.6MBKD
$187.2MVERA
$168.1MIONS
$157.0MCELC
$151.8MBCRX
$151.0MNAMS
$144.5MACHC
$133.5MTNGX
$131.0M
Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.
13fpro.ai/research/fund/deerfield-management-company-l-p-series-c-1009258
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 13F holdings — Q2 2026
$9.6B portfolio (+13.1% QoQ) · 82 holdings · Q2 2026 13F · top 10 are 53% of the stock portfolio
$2.1B
22.2% of stocks
No changeThis quarter—Since filed10+ qtrsHeld- 2
BROOKDALE SR LIVING INC - NOTE 3.500%10/1
$585.7M
6.1% of stocks
No changeThis quarter—Since filed—HeldAIQuality—Est. buy— $448.0M
4.7% of stocks
+4%This quarter-9.7%Since filed10+ qtrsHeld$322.5M
3.4% of stocks
No changeThis quarter-27.1%Since filed6 qtrsHeld$320.9M
3.4% of stocks
No changeThis quarter+12.7%Since filed10+ qtrsHeld$314.6M
3.3% of stocks
-17%This quarter+0.8%Since filed10+ qtrsHeldAIQuality58.2#1,027Est. buyEstimated buy price is Pro: unlock with a free trialTrimmed 3 qtrs in a row$251.7M
2.6% of stocks
NewThis quarter-9.7%Since filedNew this quarterHeld$247.6M
2.6% of stocks
No changeThis quarter+18.6%Since filed6 qtrsHeld- 9
ARROWHEAD PHARMACEUTICALS IN - NOTE 1/1
$240.5M
2.5% of stocks
No changeThis quarter—Since filed—HeldAIQuality—Est. buy— $235.0M
2.5% of stocks
+6%This quarter+0.1%Since filed7 qtrsHeldAIQualityAI quality score is Pro: unlock with a free trialEst. buyEstimated buy price is Pro: unlock with a free trialAdded 3 qtrs in a row
All holdings — DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (Q2 2026)
82 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.
| # | Company | Held | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | Cogent Biosciences, Inc. | Healthcare | $193.7M | 2.0% | 5.01M | -45% | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 12 | GENMAB A/Sadr | Healthcare | $188.6M | 2.0% | 6.87M | +179% | 2 qtrsAdded 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 13 | Brookdale Senior Living Inc. | Healthcare | $187.2M | 1.9% | 11.64M | — | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 14 | Vera Therapeutics, Inc. | Healthcare | $168.1M | 1.8% | 3.92M | +5% | 6 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 15 | IONIS PHARMACEUTICALS INC | Healthcare | $157.0M | 1.6% | 1.98M | — | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 16 | Celcuity Inc. | Healthcare | $151.8M | 1.6% | 1.45M | -15% | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 17 | BIOCRYST PHARMACEUTICALS INC | Healthcare | $151.0M | 1.6% | 15.10M | +0.4% | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 18 | NewAmsterdam Pharma Co N.V. | Healthcare | $144.5M | 1.5% | 4.26M | — | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 19 | Acadia Healthcare Company, Inc. | Healthcare | $133.5M | 1.4% | 4.52M | — | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 20 | Tango Therapeutics, Inc. | Healthcare | $131.0M | 1.4% | 4.19M | +1% | 3 qtrsAdded 3 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 21 | AdaptHealth Corp. | Healthcare | $119.6M | 1.3% | 11.48M | — | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 22 | Pharvaris N.V. | Healthcare | $116.7M | 1.2% | 3.38M | +8% | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 23 | Celcuity Inc.note | Healthcare | $113.8M | 1.2% | 100.00M | New | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 24 | ARROWHEAD PHARMACEUTICALS, INC. | Healthcare | $113.2M | 1.2% | 1.39M | -12% | 4 qtrsTrimmed 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 25 | Dianthus Therapeutics, Inc. /DE/ | Healthcare | $109.7M | 1.1% | 1.13M | +10% | 2 qtrsAdded 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 26 | $LRMR | Larimar Therapeutics, Inc. | Healthcare | $108.6M | 1.1% | 35.61M | — | |||
| 27 | $MLYS | Mineralys Therapeutics, Inc. | Healthcare | $106.8M | 1.1% | 3.96M | New | |||
| 28 | $ALHC | Alignment Healthcare, Inc. | Healthcare | $103.8M | 1.1% | 61.00M | — | |||
| 29 | $IDYA | IDEAYA Biosciences, Inc. | Healthcare | $101.2M | 1.1% | 2.71M | +77% | |||
| 30 | $XENE | Xenon Pharmaceuticals Inc. | Healthcare | $97.5M | 1.0% | 1.62M | — | |||
| 31 | $IONS | IONIS PHARMACEUTICALS INC | Healthcare | $93.1M | 1.0% | 60.00M | — | |||
| 32 | $SVRA | Savara Inc | Healthcare | $83.6M | 0.9% | 13.57M | — | |||
| 33 | $LNTH | Lantheus Holdings, Inc. | Healthcare | $83.5M | 0.9% | 753K | -9% | |||
| 34 | $SNDX | Syndax Pharmaceuticals Inc | Healthcare | $82.6M | 0.9% | 3.78M | — | |||
| 35 | — | ZENAS BIOPHARMA INC - NOTE 2.500% 4/0 | — | $80.3M | 0.8% | 67.20M | +3% | |||
| 36 | $BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $76.3M | 0.8% | 1.33M | +57% | |||
| 37 | $PFE | PFIZER INC | Healthcare | $73.2M | 0.8% | 3.04M | — | |||
| 38 | $INDV | Indivior Pharmaceuticals, Inc. | Healthcare | $67.7M | 0.7% | 1.65M | -47% | |||
| 39 | $BIO | BIO-RAD LABORATORIES, INC. | Healthcare | $66.4M | 0.7% | 226K | — | |||
| 40 | $SPRY | ARS Pharmaceuticals, Inc. | Healthcare | $60.1M | 0.6% | 7.50M | — | |||
| 41 | $STOK | Stoke Therapeutics, Inc. | Healthcare | $59.7M | 0.6% | 1.82M | — | |||
| 42 | $GPCR | Structure Therapeutics Inc. | Healthcare | $58.3M | 0.6% | 1.09M | +41% | |||
| 43 | $NVST | Envista Holdings Corp | Healthcare | $58.2M | 0.6% | 2.21M | — | |||
| 44 | $INSP | Inspire Medical Systems, Inc. | Healthcare | $57.9M | 0.6% | 1.30M | -52% | |||
| 45 | $CDNA | CareDx, Inc. | Healthcare | $56.9M | 0.6% | 2.00M | -9% | |||
| 46 | $BSX | BOSTON SCIENTIFIC CORP | Healthcare | $56.1M | 0.6% | 1.31M | New | |||
| 47 | $BLTE | BELITE BIO, INC | Healthcare | $55.0M | 0.6% | 357K | +17% | |||
| 48 | $PBLS | Parabilis Medicines, Inc. | Healthcare | $51.5M | 0.5% | 1.88M | New | |||
| 49 | $CERT | Certara, Inc. | Technology | $49.2M | 0.5% | 7.51M | -4% | |||
| 50 | $IRON | Disc Medicine, Inc. | Healthcare | $48.1M | 0.5% | 657K | — | |||
| 51 | $LIVN | LivaNova PLC | Healthcare | $46.5M | 0.5% | 34.28M | — | |||
| 52 | $BBOT | BridgeBio Oncology Therapeutics, Inc. | Healthcare | $37.2M | 0.4% | 4.89M | — | |||
| 53 | $TYRA | Tyra Biosciences, Inc. | Healthcare | $32.5M | 0.3% | 1.02M | +85% | |||
| 54 | $MNPR | Monopar Therapeutics | Healthcare | $30.0M | 0.3% | 324K | — | |||
| 55 | $SION | Sionna Therapeutics, Inc. | Healthcare | $30.0M | 0.3% | 681K | -30% | |||
| 56 | $IMCR | Immunocore Holdings plc | Healthcare | $27.1M | 0.3% | 30.00M | — | |||
| 57 | $AVLN | Avalyn Pharma Inc. | Healthcare | $24.1M | 0.3% | 731K | New | |||
| 58 | $FHTX | Foghorn Therapeutics Inc. | Healthcare | $21.4M | 0.2% | 4.39M | — | |||
| 59 | $BBNX | Beta Bionics, Inc. | Healthcare | $20.7M | 0.2% | 1.32M | — | |||
| 60 | $ALNY | ALNYLAM PHARMACEUTICALS, INC. | Healthcare | $20.5M | 0.2% | 68K | — | |||
| 61 | $DRUG | BRIGHT MINDS BIOSCIENCES INC. | Healthcare | $19.9M | 0.2% | 283K | — | |||
| 62 | $ODTX | Odyssey Therapeutics, Inc. | Healthcare | $19.6M | 0.2% | 1.05M | New | |||
| 63 | $STLN | Starling Oncology, Inc. | Healthcare | $18.2M | 0.2% | 3.36M | — | |||
| 64 | $KYTX | Kyverna Therapeutics, Inc. | Healthcare | $17.8M | 0.2% | 2.00M | — | |||
| 65 | $ALMR | Alamar Biosciences, Inc. | Healthcare | $16.3M | 0.2% | 600K | New | |||
| 66 | $CHE | CHEMED CORP | Healthcare | $14.0M | 0.1% | 30K | New | |||
| 67 | $SGP | SpyGlass Pharma, Inc. | Healthcare | $12.2M | 0.1% | 550K | — | |||
| 68 | $NEO | NEOGENOMICS INC | Technology | $12.2M | 0.1% | 13.04M | -82% | |||
| 69 | $ADAG | Adagene Inc. | Healthcare | $11.2M | 0.1% | 2.67M | New | |||
| 70 | $COAG | Hemab Therapeutics Holdings, Inc. | Healthcare | $10.1M | 0.1% | 275K | New | |||
| 71 | $MOBI | Mobia Medical, Inc. | Healthcare | $9.0M | 0.1% | 671K | New | |||
| 72 | $EMBC | Embecta Corp. | Healthcare | $8.3M | 0.1% | 2.53M | — | |||
| 73 | $VCYT | VERACYTE, INC. | Healthcare | $5.9M | 0.1% | 101K | -86% | |||
| 74 | $ANNX | Annexon, Inc. | Healthcare | $3.3M | 0.0% | 584K | — | |||
| 75 | $ALEC | Alector, Inc. | Healthcare | $2.1M | 0.0% | 1.06M | — | |||
| 76 | $NAMS | NewAmsterdam Pharma Co N.V. | Healthcare | $2.0M | 0.0% | 93K | — | |||
| 77 | $EW | Edwards Lifesciences Corp | Healthcare | $1.2M | 0.0% | 14K | — | |||
| 78 | $MIRM | Mirum Pharmaceuticals, Inc. | Healthcare | $706K | 0.0% | 6,027 | -100% | |||
| 79 | $HUM | HUMANA INC | Healthcare | $364K | 0.0% | 917 | — | |||
| 80 | $STLN | Starling Oncology, Inc. | Healthcare | $51K | 0.0% | 1.25M | — | |||
| 81 | $PMVP | PMV Pharmaceuticals, Inc. | Healthcare | $12K | 0.0% | 8,790 | — | |||
| 82 | $SRZN | Surrozen, Inc./DE | Healthcare | $3K | 0.0% | 167K | — |
What changed in Q2 2026
Against the previous quarter's 13F: 10 new, 14 added to, 13 trimmed, 12 sold out. Share-count changes; largest moves by dollar size first.
New positions (10)
$MLYSMineralys Therapeutics, Inc.$106.8M
first bought this quarter
$BSXBOSTON SCIENTIFIC CORP$56.1M
first bought this quarter
$PBLSParabilis Medicines, Inc.$51.5M
first bought this quarter
$AVLNAvalyn Pharma Inc.$24.1M
first bought this quarter
$ODTXOdyssey Therapeutics, Inc.$19.6M
first bought this quarter
$ALMRAlamar Biosciences, Inc.$16.3M
first bought this quarter
+4 more in the Excel export
Added to (14)
now $188.6M · held 2 qtrs, 2 adds in a row
$IDYAIDEAYA Biosciences, Inc.+77%
now $101.2M · held 10+ qtrs
$BMRNBIOMARIN PHARMACEUTICAL INC+57%
now $76.3M · held 2 qtrs, 2 adds in a row
now $448.0M · held 10+ qtrs
$GPCRStructure Therapeutics Inc.+41%
now $58.3M · held 10+ qtrs
$TYRATyra Biosciences, Inc.+85%
now $32.5M · held 2 qtrs, 2 adds in a row
+8 more in the Excel export
Trimmed (13)
$MIRMMirum Pharmaceuticals, Inc.-100%
now $706K · held 9 qtrs
now $193.7M · held 10+ qtrs
now $314.6M · held 10+ qtrs, 3 trims in a row
$INSPInspire Medical Systems, Inc.-52%
now $57.9M · held 5 qtrs
$INDVIndivior Pharmaceuticals, Inc.-47%
now $67.7M · held 8 qtrs, 4 trims in a row
$NEONEOGENOMICS INC-82%
now $12.2M · held 5 qtrs
+7 more in the Excel export
Sold out (12)
$CPRXCATALYST PHARMACEUTICALS, INC.was $97.6M
held 9+ qtrs
$NBIXNEUROCRINE BIOSCIENCES INCwas $80.4M
held 9+ qtrs
$DAWNDay One Biopharmaceuticals, Inc.was $79.8M
held 9+ qtrs
$EHABEnhabit, Inc.was $66.9M
held 9+ qtrs
$KYMRKymera Therapeutics, Inc.was $46.7M
$CMPXCompass Therapeutics, Inc.was $19.1M
+6 more in the Excel export
Holdings by quarter
Every 13F DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) has filed, 40 earlier quarters. Pick one to see what it held then.
Is it too late to follow DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)?
Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.
Average quality of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s top 20 holdings: 46/100 (our AI quality score, weighted by position size; 12 of the 20 are scored)
Top 10 since filing
-8.3%
Value-weighted move of the 10 largest stock positions
Turnover
17%
Last quarter; 70% over the last 4
Top 10 weight
53%
Share of the stock portfolio in its 10 largest positions
Held 4+ quarters
86%
Share of portfolio value in positions held a year or more
Highest-quality names it owns(among its 100 largest positions)
The 8 highest-scoring companies in this portfolio are a Pro feature.
How these are measured
- Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
- Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
- Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
- Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
- Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.
Portfolio Overview
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) disclosed 82 positions worth $9.6B in its Form 13F-HR for Q2 2026, led by $NUVL (Nuvalent, Inc.) at 22.2% of the equity portfolio. During the quarter the fund opened 10 new positions and exited 12 — including a new stake in $MLYS and a full exit from $CPRX. The portfolio is most concentrated in Healthcare (89.9% of disclosed assets). All figures are sourced directly from DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)’s Form 13F-HR filing with the SEC under CIK 1009258.
Funds like this
managers whose biggest positions overlap DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'sBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
AI-Powered Hedge Fund Analysis: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
13F Pro is an AI hedge fund tracker and stock research platform. For DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (SEC CIK: 1009258), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.